March 15, 2007 -- NPS Pharma will cut its staff by 82% to save cash; Lilly withdrew its request for European approval of Arxxont, an drug for blindness caused by diabetic retinopathy; Ortho-McNeil won a six-month extension of its marketing exclusivity for antibiotic Levaquin; the FDA will require Sepracor and Sanofi-Aventis to put sleep-walking warnings on their blockbuster sedatives Lunestra and Ambien; and Oscient fell lower after it proposed to float $215.5 million in new 3.5% notes; The Centient Biotech 200™ eked out a small fractional gain to end at 3806, a rise of .01%. More details...
